Advertise on podcast: GLP-1 Daily: Ozempic & Wegovy News

Tirzepatide access for about 400 patients in Urupês, Brazil, is disrupted after a court suspended a municipal compounded-drug program over regulatory compliance questions. The dispute concerns compounded medication, not branded Mounjaro; patients facing treatment interruptions should consult their prescriber about continuity of care. In this episode: Top stories: 1. Justice suspends Bolsa Mounjaro program in Urupês SP — Juri News https://jurinews.com.br/en/destaques-ultimas/justice-suspends-program-of-mounjaro-free-in-sao-paulo-city-and-leaves-400-patients-without-treatment 2. New OAC Research and FDA Guidance Put Medication Apps in the Spotlight - Obesity Action Coalition — Obesity Action Coalition https://www.obesityaction.org/new-oac-research-and-fda-guidance-put-medication-apps-in-the-spotlight/ 3. Lilly at ObesityWeek: weight maintenance, Foundayo, amylin — Dr. Asnat Raziel https://en.asnatraziel.com/lilly-at-obesityweek/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

Good Life Meds faces an advertising watchdog’s recommendation to drop unsupported compounded tirzepatide claims, while Novo Nordisk accelerates its Wegovy pill rollout. Ask your prescriber what product-specific evidence and access options mean for your care. In this episode: Top stories: 1. National Advertising Division Recommends Good Life — GlobeNewswire https://www.globenewswire.com/news-release/2026/11/04/3395623/0/en/national-advertising-division-recommends-good-life-discontinue-health-benefit-and-personalization-claims-for-compounded-tirzepatide-products.html 2. Novo catches Wegovy pill tailwind in Q3 as CEO eyes new launch horizons in 2027 | Fierce Pharma — Fierce Pharma https://www.fiercepharma.com/pharma/novo-catches-wegovy-pill-tailwind-q3-ceo-eyes-new-launch-horizons-2027 3. Camurus AB: Camurus initiates Phase 2b study of CAM2056 monthly semaglutide depot in obesity - Inderes — Inderes https://www.inderes.se/en/releases/camurus-ab-camurus-initiates-phase-2b-study-of-cam2056-monthly-semaglutide-depot-in-obesity Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

The FDA sent a warning letter to RonanRx over how it marketed compounded semaglutide and tirzepatide, and New Zealand's Pharmac says Wegovy for weight loss remains unfunded despite a high-priority recommendation. Plus, obesity doctors respond to a study estimating more than a million Americans may take GLP-1s off-label. In this episode: 1. RonanRx, Inc. dba RonanRx - 737905 - 10/30/2026 — U.S. Food and Drug Administration http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026 2. Wegovy and Mounjaro for weight loss not funded - Pharmac | Te Pātaka Whaioranga | NZ Government — Pharmac, Te Pātaka Whaioranga, NZ Government https://www.pharmac.govt.nz/news-and-resources/news/semaglutide-wegovy-ozempic 3. A Million People in US May Take GLP-1s Off-Label — Virginia Anderson https://www.medscape.com/viewarticle/million-people-us-may-take-glp-1s-label-2026a10015rv?src=rss Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

An advocacy group is pushing Ohio to rewrite the rule that keeps its Medicaid program from covering GLP-1s for adult obesity, while a large, preliminary health-records study for the American Heart Association links GLP-1s to better prediabetes outcomes than metformin. Australia's drug regulator has also approved the Wegovy pill. In this episode: 1. Group seeks Ohio Medicaid coverage for GLP-1 weight-loss drugs — Daytondailynews https://www.daytondailynews.com/local/group-seeks-ohio-medicaid-coverage-for-glp-1-weight-loss-drugs/article_0d19a1fa-78ee-5889-b5cd-09f7fff19ac8.html 2. GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med | American Heart Association — American Heart Association https://newsroom.heart.org/news/glp-1-meds-linked-to-lower-diabetes-heart-risks-than-standard-diabetes-prevention-med 3. Watchdog’s huge call on weight-loss drug pill - Yahoo News Australia — Emma Kirk https://au.news.yahoo.com/watchdog-huge-call-weight-loss-080931994.html Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

As employers drop weight-loss GLP-1 coverage for 2027, Novo Nordisk's deal with Andel and GoodRx's new Employer Direct let companies chip in on cash prices outside insurance. Plus: South Korea's prescriptions and intercepted illegal imports surge, and Sun Pharma gets Indian approval for a generic semaglutide diabetes pill. In this episode: 1. As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround — Ajmc https://www.ajmc.com/view/as-employers-pull-back-on-glp-1s-andel-and-novo-offer-a-workaround 2. Koreans aren't rushing to embrace homegrown weight-loss drug — yet | Aju Press — Aju Press https://www.ajupress.com/view/20261102161600077 3. Sun Pharma Secures Approval for Generic Semaglutide Pill in India, ETPharma — Abhijeet Singh https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/sun-pharma-wins-cdsco-nod-for-semaglutide-pill/135385080 Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

A preliminary Truveta analysis finds GLP-1 prescribing to adults 65 and older stayed about 21 percent above June levels three months after the Medicare GLP-1 Bridge launched, while Hanmi's Eppe began prescriptions in South Korea at a starter price undercutting Mounjaro and Wegovy. A Novo-funded pooled analysis of SELECT, FLOW and SOUL links semaglutide to fewer major kidney outcomes. In this episode: 1. GLP-1 prescriptions still up three months into Medicare Bridge pilot — Truveta Research https://www.truveta.com/blog/research/glp-1-medicare-bridge-3-month-prescribing/ 2. Korea’s First Homegrown Obesity Drug Begins Prescriptions, Challenging Mounjaro on Price - Businesskorea — Choi Mun-hee https://www.businesskorea.co.kr/news/articleView.html?idxno=279957 3. Semaglutide Slows Kidney Function Decline in High-Risk Patients — Lisa Kuhns, PhD https://www.endocrinologyadvisor.com/news/semaglutide-slows-kidney-function-decline-high-risk-patients/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

Eli Lilly reports company topline phase 3 results showing its experimental retatrutide beat Ozempic 2 mg on blood sugar and weight in type 2 diabetes, with more side-effect dropouts. HHS paused enforcement against pharmacies compounding six unapproved peptides, and a JAMA study from Nebraska finds compounded GLP-1s widely mixed with B12 and other additives. In this episode: 1. Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial — Jonathan Gardner https://www.biopharmadive.com/news/retatrutide-ozempic-diabetes-trial-results-lilly-novo/873016/ 2. RFK Jr. takes shortcut to make some unapproved peptides available for use — NBC News https://www.nbcnews.com/health/health-news/rfk-jr-takes-shortcut-make-peptides-widely-available-rcna606133 3. Compounded GLP-1s Coformulated With B12, Other Additives — Marilynn Larkin https://www.medscape.com/viewarticle/compounded-glp-1s-widely-coformulated-vitamin-b12-and-other-2026a100150m Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

A WTW survey reported by CNBC finds employer coverage of weight-loss GLP-1s falling for the first time in three years, as Walgreens rolls out prior-authorization and Medicare Bridge help. Vanda says its pill tradipitant cut semaglutide-induced vomiting in a company-reported phase 3 trial. In this episode: 1. GLP-1 coverage is being dropped by employers: 2027 weight-loss options — CNBC https://www.cnbc.com/2026/10/27/glp1-drug-coverage-weight-loss-options.html 2. Walgreens Adds Pharmacist Outreach, Coverage Help for GLP ... — Pharmacy Times https://www.pharmacytimes.com/view/walgreens-adds-pharmacist-outreach-coverage-help-for-glp-1s 3. Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial — Hcplive https://www.hcplive.com/view/tradipitant-cuts-semaglutide-induced-vomiting-in-phase-3-trial Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

A federal judge on Monday refused Novo Nordisk's bid to halt Eli Lilly's comparative weight-loss ads while the suit continues, and South Korea's health minister put obesity drugs up for a managed-insurance review at a hearing that exposed ignored prescribing alerts. Plus, generic semaglutide maker Dr. Reddy's aims to restart supply in November if validation succeeds. In this episode: 1. US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk — StreetInsider https://www.streetinsider.com/Reuters/US+judge+refuses+to+block+Eli+Lilly+weight-loss+drug+ads%2C+rules+against+Novo+Nordisk/27234058.html 2. Korea Weighs Putting Obesity Drugs Under Health Insurance Controls - Seoul Economic Daily — Park Hong-yong https://en.sedaily.com/technology/2026/10/27/korea-weighs-putting-obesity-drugs-under-health-insurance 3. Dr Reddy's Plans 6-7 Million Semaglutide Pens by March — Drew Thornley https://www.peptideandprotein.com/articles/dr-reddys-semaglutide-relaunch-abatacept-aurigene-q2-fy27/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

South African regulators admit they're on the back foot against bulk-compounded and black-market weight-loss jabs, and Belgium refuses to reimburse Mounjaro for obesity. A JAMA Network Open study finds about half of early Wegovy pill starters were new to GLP-1s. In this episode: 1. SA regulators struggle to control illegal weight-loss jabs — Daily Maverick https://www.dailymaverick.co.za/article/2026-10-23-sas-regulators-are-struggling-to-keep-up-with-black-market-weight-loss-jabs/?dm_campaign=inform&dm_medium=card-link&dm_position=1&dm_source=blocks-grid 2. Belgium Rejects Reimbursement for Mounjaro in Obesity Treatment | NAVLIN DAILY — NAVLIN DAILY https://www.navlindaily.com/article/32278/belgium-rejects-reimbursement-for-mounjaro-in-obesity-treatment 3. Oral Semaglutide Uptake Near Injectable Levels Within 3 ... — AJMC https://www.ajmc.com/view/oral-semaglutide-uptake-near-injectable-levels-within-3-months Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

Mass General Brigham confirms affected employee plans will stop covering GLP-1s for weight loss on January 1, 2027, and British MPs say the NHS plan for Mounjaro reaches only about 6% of eligible people. CBS News lab-tested vials sold as retatrutide and found one held no peptide at all, plus bacteria. In this episode: 1. EXCLUSIVE: Mass General Helped Give the World GLP-1. Now Its Own Benefits Are Pulling Back Obesity Drug Coverage | On The Pen — On The Pen GLP-1 News https://onthepen.com/news/exclusive-mass-general-helped-give 2. Give more people weight loss jabs on the NHS, say MPs - BBC News — BBC News https://www.bbc.co.uk/news/articles/cm4g1pkwxdqwo 3. We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying." - CBS News — Adam Yamaguchi Correspondent https://www.cbsnews.com/news/tested-experimental-weight-loss-drug-results/ Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

A Los Angeles judge sent a patient's lawsuit, which says Anthem cut off Zepbound because it worked, to private arbitration. Also today: telehealth companies offering GLP-1s off-label for addiction, and what the SOUL trial does and doesn't show about oral semaglutide and the kidneys. In this episode: 1. Obese Woman Ordered to Arbitrate Claims vs. Anthem Over Zepbound Denial - MyNewsLA.com — Mynewsla https://mynewsla.com/orange-county/2026/10/20/obese-woman-ordered-to-arbitrate-claims-vs-anthem-over-zepbound-denial/ 2. STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction — STAT https://www.statnews.com/2026/10/22/glp-1-drugs-substance-use-disorder-telehealth-off-label-prescription/?utm_campaign=rss 3. Oral Semaglutide Kidney Outcomes in SOUL | PeptideMethods — PeptideMethods https://peptidemethods.com/blog/oral-semaglutide-kidney-soul-trial Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

An FDA inspection report details 14 problems at Houston RX, the pharmacy behind a nationwide recall of compounded tirzepatide vials, while Belgium's medicines agency warns against off-label GLP-1 use and black-market retatrutide. Plus, Novo's company-reported CagriSema data in women ahead of an expected FDA decision. In this episode: 1. Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients — Medical Daily https://www.medicaldaily.com/houston-rx-fda-483-compounded-tirzepatide-recall-sterility-480121 2. GLP-1 analogues and GIP/GLP-1 dual analogues: risks associated with misuse and off-label use for weight loss | FAMHP — FAMHP https://www.faag.be/en/news/glp_1_analogues_and_gipglp_1_dual_analogues_risks_associated_with_misuse_and_off_label_use_for 3. CagriSema Weight Loss in Women | Novo Nordisk U.S. — Novo Nordisk U.S. https://www.novonordisk-us.com/media/press-releases/cagrisema-redefine1-weight-loss-women-menopause.html Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

FDA inspection reports describe mold, insects and hidden records at two Chinese suppliers of compounded semaglutide and tirzepatide ingredients, now on import alert. Plus a Health Affairs Scholar study on first-fill GLP-1 denials, and the EU drug regulator's committee backing Lilly's Foundayo pill. In this episode: 1. FDA Flags Chinese GLP-1 Ingredient Suppliers — Kalbir Talwar https://www.briefs.co/news/fda-flags-two-chinese-makers-of-compounded-glp-1-ingredients/ 2. Prescription Denials For GLP-1 Receptor Agonists Across Commercial, Medicare, And Medicaid Coverage, 2018–2024 | Health Affairs Scholar | Oxford Academic — Jia, Miaoqing, Levy, Joseph F, McGinty, Emma E, Tummalapalli, Sri Lekha, Zhang, Yongkang https://academic.oup.com/healthaffairsscholar/advance-article/doi/10.1093/haschl/qxag284/8922286 3. EMA CHMP Backs Orforglipron (Foundayo): Non-Peptide GLP-1 EU Approval Implications — BSR — Biotech Research https://biotechresearch.co.uk/intelligence/emas-chmp-backs-orforglipron-for-the-eu-what-the-non-peptide-glp-1-opinion-means-for-the-research-landscape Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]

CBS News obtained two unverified FDA adverse-event reports of deaths after use of products sold as retatrutide, and Walmart will make Ozempic and Mounjaro free in 2027 for employees with type 2 diabetes but still won't cover GLP-1s for weight loss. Plus, a new Annals of Internal Medicine paper finds the Wegovy pill passed 100,000 monthly new prescriptions within two months of launch. In this episode: 1. Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? - CBS News — Daniel Gilbert Investigative Reporter https://www.cbsnews.com/news/deaths-reported-fda-bootleg-reta-weight-loss-drug/ 2. Walmart employee benefits add no-cost GLP-1s in 2027 — CNBC https://www.cnbc.com/2026/10/13/walmart-glp-1s-inhalers-insulin-employee-benefits.html 3. Oral Semaglutide Obesity Rx Tops 100K Monthly in 2 Months — Medscape https://www.medscape.com/viewarticle/oral-semaglutide-obesity-rx-tops-100k-monthly-2-months-2026a100124c?src=rss Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email [email protected]